Linked Life Data

7960234

Source:http://linkedlifedata.com/resource/pubmed/id/7960234

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1994-12-23
pubmed:abstractText
The protein product of the bcl-2 gene is though to be involved in inhibition of apoptosis; it may therefore be important in the modulation of hormonal/anti-hormonal responsiveness exhibited by tumours. This study immunocytochemically investigates (i) relationships between bcl-2 protein expression in primary breast cancers and other markers of prognostic and therapeutic value and (ii) associations of the bcl-2 protein with breast cancer responsiveness to endocrine therapy. The bcl-2 protein was found within the tumour epithelial cell cytoplasm of 32/46 breast cancer specimens; inter-patient staining was heterogeneous. Immunostaining for steroid hormone receptors was strongly associated with that for the bcl-2 protein, and it is thus possible that this protein, like progesterone receptor, is under oestrogen regulation via oestrogen receptor. The protein was inversely related to 2 markers of endocrine insensitivity, epidermal growth factor receptor (EGFR) and c-erbB-2 oncoprotein, while no associations were observed with either transforming growth factor (TGF)-alpha or Ki-67 proliferative status. A highly significant relationship was observed between response to endocrine therapy and the presence of bcl-2 protein. Indeed, bcl-2 immunostaining proved to be a more accurate predictor of response than oestrogen receptor status. Patients with elevated bcl-2 immunostaining (particularly those who coexpressed high oestrogen receptor levels) appeared to derive the greatest benefit from endocrine therapy. Our results are paradoxical since it was expected that the bcl-2 protein would counteract the tumour inhibitory effects of endocrine therapies as it is thought to prevent programmed cell death.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0020-7136
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
59
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
619-28
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:7960234-Apoptosis, pubmed-meshheading:7960234-Breast Neoplasms, pubmed-meshheading:7960234-Cell Nucleus, pubmed-meshheading:7960234-Cytoplasm, pubmed-meshheading:7960234-Epithelium, pubmed-meshheading:7960234-Female, pubmed-meshheading:7960234-Goserelin, pubmed-meshheading:7960234-Humans, pubmed-meshheading:7960234-Immunoenzyme Techniques, pubmed-meshheading:7960234-Prognosis, pubmed-meshheading:7960234-Proto-Oncogene Proteins, pubmed-meshheading:7960234-Proto-Oncogene Proteins c-bcl-2, pubmed-meshheading:7960234-Receptor, Epidermal Growth Factor, pubmed-meshheading:7960234-Receptors, Estrogen, pubmed-meshheading:7960234-Receptors, Progesterone, pubmed-meshheading:7960234-Tamoxifen, pubmed-meshheading:7960234-Transforming Growth Factor alpha, pubmed-meshheading:7960234-Tumor Markers, Biological
pubmed:year
1994
pubmed:articleTitle
Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy.
pubmed:affiliation
Breast Cancer Unit, University of Wales College of Medicine, Cardiff, UK.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't